Clobetasol propionate cream 0.025%: a topical therapeutic for dermatological disorders

Authors

  • Gnansekaran R. Department of Dermatology, Kaya Clinic, Madurai, Tamil Nadu, India
  • Chand Mohammad Department of Dermatology, Domkal Super speciality Hospital, Baharampur, West Bengal, India
  • Nirmal Kumar Saini Department of Dermatology, Skin Care Clinic, Sri Ganganagar, Rajasthan, India
  • Vivek Aggarwal Department of Dermatology, Vivek Skin Care Clinic, Kurukshetra, Haryana, India
  • Sameer Mishra Department of Dermatology, Berkowits Hair And Skin Clinic, New Delhi, India
  • Surjit Singh Mehta Department of Dermatology, Fortis Hospital, Delhi, India
  • Bhabhor Rahul Satvantsinh Department of Dermatology, Divyanshi Skin & Cosmetic Clinic, Dahod, Gujarat, India
  • Mure Sri Hari Prasanna Department of Dermatology, Sri Haari Skin Hospital, Rajahmundry, Andhra Pradesh, India
  • Satu Srikanth Department of Dermatology, Aadhya Skin Hair & Laser Clinic, Warangal, Telangana
  • Alka Gupta Department of Dermatology, Gupta Clinic, Janakpuri, New Delhi, India

DOI:

https://doi.org/10.18203/2320-6012.ijrms20221021

Keywords:

Clobetasol propionate 0.025%, Plaque psoriasis, Psoriasis, Topical corticosteroids

Abstract

Due to the anti-inflammatory and vasodilator effects of topical corticosteroids, they help in treating atopic eczema, psoriasis, chronic hand eczema, and localized vitiligo, among other dermatological diseases. Clobetasol propionate (CP) is the most popular topical medication used to treat plaque psoriasis. It has anti-inflammatory, antimitotic, antipruritic, and immunosuppressive characteristics. The USFDA has approved CP 0.025% cream for the treatment of moderate-to-severe psoriasis in adults. Propylene glycol, short-chain alcohols, and sorbitol-based emulsifiers are all recognized contact allergens, and the formulation has exhibited hypoallergenic effects. CP 0.025% is an effective and safe agent due to its high active ingredient penetration and minimal systemic absorption. The clinical experience of employing CP 0.025% cream in diverse dermatologic disorders is discussed in this case series, with a focus on its efficacy and safety.

References

Siegfried EC, Hebert AA. Diagnosis of Atopic Dermatitis: Mimics, Overlaps, and Complications. J Clin Med. 2015;4(5):884-917.

Rosso JQ. Topical Corticosteroid Therapy for Psoriasis-A Review of Clobetasol Propionate 0.025% Cream and the Clinical Relevance of Penetration Modification. J Clin Aesthet Dermatol. 2020;13(2):22-9.

Gabros S, Nessel TA, Zito PM. Topical Corticosteroids. StatPearls. Treasure Island, FL: StatPearls Publishing; 2022.

Draelos ZD, Fowler JF, Cornelison R. A randomized, parallel group, open label, multicenter study to assess the potential for adrenal suppression and systemic drug absorption following multiple dosing with clobetasol propionate cream (Impoyz™), 0.025% versus clobetasol propionate (Temovate®). Skin JCMS. 2018;2(6).

Dopytalska K, Sobolewski P, Błaszczak A. Psoriasis in special localizations. Reumatologia. 2018;56(6):392.

Singh JK, Zanwar YR, Kumar J. Role of topical corticosteroid therapy in various dermatoses. Int J Res Med Sci 2021;9:34-41.

USFDA. Impoyz (Clobetasol propionate Cream, 0.025%), 2017. Available at: https://www.access data.fda.gov/drugsatfda_docs/nda/2017/209483Orig1s000MedR. Accessed on 4th March 2022.

Downloads

Published

2022-04-26

How to Cite

R., G., Mohammad, C., Saini, N. K., Aggarwal, V., Mishra, S., Mehta, S. S., Satvantsinh, B. R., Prasanna, M. S. H., Srikanth, S., & Gupta, A. (2022). Clobetasol propionate cream 0.025%: a topical therapeutic for dermatological disorders. International Journal of Research in Medical Sciences, 10(5), 1169–1175. https://doi.org/10.18203/2320-6012.ijrms20221021

Issue

Section

Case Series